A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants and Toddlers.

Trial Profile

A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants and Toddlers.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2013

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Hib-DTaP-hepatitis B-poliovirus vaccine; Meningococcal vaccine group C conjugate; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Pertussis; Pneumococcal infections; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Most Recent Events

    • 19 Sep 2011 Trial status for the extension trial (NCT01345721) is changed from recruiting to completed.
    • 19 Sep 2011 Trial status for the extension trial (NCT01345721) is changed from recruiting to completed.
    • 19 Sep 2011 Actual end date (Sept 2011) added as reported by ClinicalTrials.gov (Extension trial NCT01345721).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top